Bio Pharma Dive
AUGUST 18, 2023
BSCA has kicked CVS Caremark, the largest pharmacy benefit manager in the country, to the curb and is electing to carve out various pharmacy functions with companies like Amazon instead.
Pharmaceutical Technology
AUGUST 18, 2023
Bruker has entered into a definitive agreement to acquire functional cell biology company PhenomeX for a total equity value of $108m.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
AUGUST 18, 2023
The treatment, which Merck picked up through a 2019 acquisition of Peloton Therapeutics, helped delay disease progression in patients with advanced renal cell carcinoma.
Pharmaceutical Technology
AUGUST 18, 2023
The decision brings the first daily oral migraine prophylactic to Europe, with plans to rollout the treatment as soon as possible.
Bio Pharma Dive
AUGUST 18, 2023
But the demand for booster shots ahead of an expected surge of infections this fall remains an unanswered question weighing heavily on Moderna’s future outlook.
Pharmaceutical Technology
AUGUST 18, 2023
Astellas Pharma has announced that EMA has accepted the MAA from its subsidiary Iveric Bio for the review of ACP to treat GA.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
AUGUST 18, 2023
Depending on Phase III results, survodutide could soon enter the weight loss market, which is expected to reach $37.1bn by 2031.
XTalks
AUGUST 18, 2023
After Johnson & Johnson’s US Food and Drug Administration (FDA) approval last week for its second multiple myeloma bispecific, Talvey (talquetamab), Pfizer received an FDA nod for its B-cell maturation antigen (BCMA)-directed therapy Elrexfio (elranatamab) in the same indication. Elrexfio is Pfizer’s first approved multiple myeloma drug. However, Elrexfio will be going up head-to-head against Johnson & Johnson’s BCMA-targeted therapy Tecvayli (teclistamab).
Pharmaceutical Technology
AUGUST 18, 2023
Competitive intelligence is a vital tool of the research and analysis toolbox for firms wanting valuable data on their market, competitors and customers
Fierce Pharma
AUGUST 18, 2023
It was only last spring that Biogen started a | It was only last spring that Biogen started layoffs that eventually shrank the company’s headcount by nearly 900 people last year. Now, a fresh round of job cuts targeting 1,000 positions has kicked off at the struggling drugmaker. At the same time, Biogen is spending $7.3 billion to buy rare disease specialist Reata Pharmaceuticals.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
AUGUST 18, 2023
Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.
Drug Discovery World
AUGUST 18, 2023
The UK government has announced up to £210 ($267) million of funding to partner with countries across Asia and Africa to tackle antimicrobial resistance (AMR) and reduce the threat posed to the UK. The announcement follows the £39 ($48) million investment through the Global AMR Innovation Fund (GAMRIF) in May. The money is intended to pay for new laboratories, disease surveillance systems, and a bigger global workforce.
Pharmaceutical Technology
AUGUST 18, 2023
Imugene's azercabtagene zarpreleucel (azer-cel) allo-CAR T cell therapy has shown a 58% ORR and 41% CR rate across all doses.
Outsourcing Pharma
AUGUST 18, 2023
A kidney disease drug with a âdurable and clinically meaningful impact on kidney functionâ has been granted priority review by the US Food and Drug Administration (FDA).
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
AUGUST 18, 2023
Nuvectis Pharma has received US Food and Drug Administration (FDA) orphan drug designation for NXP800 to treat cholangiocarcinoma.
Outsourcing Pharma
AUGUST 18, 2023
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
Pharmaceutical Technology
AUGUST 18, 2023
As restrictions on abortion drug mifepristone loom, doctors and patients are looking to off-label misoprostol as an alternative.
Fierce Pharma
AUGUST 18, 2023
Vexed by plummeting demand for their shots, COVID-19 vaccine producers are anxiously awaiting the fall inoculation season to get a glimpse of the post-pandemic market landscape, which includes a sh | Vexed by plummeting demand for their shots, COVID-19 vaccine producers are anxiously awaiting the fall inoculation season to get a glimpse of the post-pandemic market landscape.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharma Times
AUGUST 18, 2023
Aquablation is a robotic method that uses a high-pressure saline solution to remove tissue - News - PharmaTimes
Fierce Pharma
AUGUST 18, 2023
Along with resolving site inspection issues that cost Regeneron a high-dose Eylea launch in June, the company has scored an FDA nod for Veopoz as the first treatment for the ultra-rare inherited im | Alongside a Friday approval for its ultra-rare disease medicine Veopoz, Regeneron now expects a high-dose Eyelea nod in the next few weeks after resolving inspection issues at third-party filler Catalent.
Drug Channels
AUGUST 18, 2023
Today’s guest post is from Divya Iyer, Vice President of Strategy & Business Development, Pharma Manufacturer Solutions, at GoodRx. Divya discusses the challenges patients face in accessing specialty therapies prescribed by their healthcare providers. She suggests how the pharma industry can leverage GoodRx to help patients with access and affordability.
Fierce Pharma
AUGUST 18, 2023
Novartis’ Sandoz spinoff is right around the corner, and, to celebrate the occasion, the Swiss pharma is plotting a special stock distribution scheme. | Novartis’ Sandoz spinoff is right around the corner, and to celebrate the occasion, the Swiss pharma is plotting a special stock distribution scheme.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharma Times
AUGUST 18, 2023
The amalgamated company will focus on advancing neflamapimod for the treatment of dementia - News - PharmaTimes
Fierce Pharma
AUGUST 18, 2023
Two years after Welireg's original approval in the rare von Hippel-Lindau (VHL) disease, Merck is looking to expand its drug's reach and turn it into a blockbuster. | The drug, which was originally approved in rare von Hippel-Lindau (VHL) disease, showed improvements in progression-free survival in a phase 3 trial comparing the med with Novartis' Afinitor.
pharmaphorum
AUGUST 18, 2023
Ex-UK deputy medical officer Van-Tam takes role at Moderna Phil.
Trialfacts
AUGUST 18, 2023
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Center: Location Research Center: University of Texas at Austin Location: Health Discovery Building, 1601 TRINITY ST BLDG B, AUSTIN, TX 78712 Lead Researcher: Dr. Shelli Kesler IRB: This study has been reviewed and approved by the University of Texas at Austin Institutional Review Board About the Study Did you know that 1 in 8 women are diagnosed with breast cancer every year in the U
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
AUGUST 18, 2023
Health Innovators – Dr Jack Hoppin and Dr John Babich (follow-up) Mike.
Trialfacts
AUGUST 18, 2023
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Center: Location: Research Center: Boston University Chobanian & Avedisian School of Medicine Location: 72 E Concord St, Boston, MA 02118, USA Lead Researcher: Jesse Mez, M.D., M.S. IRB: This study has been reviewed and approved by the Advarra Institutional Review Board About the Study Are you between 55-80 years old and interested in joining the fight against Alzheimer’s?
pharmaphorum
AUGUST 18, 2023
Improving treatment for high-risk cataract surgery Mike.
Drug Discovery World
AUGUST 18, 2023
News round-up for 14-18 August by DDW Digital Content Editor Diana Spencer. My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted in the future. Next-generation antivirals could target virus membranes Researchers have shown that a group of novel molecules inspired by our own immune system inactivates viruses like Z
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
246 
Let's personalize your content